The FDA approved darolutamide for mHSPC on June 3, [2025], so we now have this in our armamentarium, along with all the other ...
Results from a phase 1/2 clinical trial (NCT05099172) show the safety and efficacy of sevabertinib (BAY2927088) in patients ...
Vorasidenib significantly improved median progression-free survival and time to next intervention in IDH-mutant grade 2 ...
Community-based CAR T-cell therapy improves access, reducing travel burdens and hospital admissions for patients with blood ...
Community-based CAR T-cell therapy expands access to innovative cancer treatments, improving patient outcomes and reducing ...
Community-based CAR T-cell therapy expands access to innovative cancer treatments, improving patient outcomes and reducing ...
A lower number of CD26+ LSCs at diagnosis correlates with optimal molecular response in CML patients at 3, 12, and 24 months.
Whole-genome sequencing (WGS) of tumor and germline can generate actionable molecular insights that can guide precision medicine efforts in salivary gland cancer (SGC), according to a new study in JCO ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback